SCHEMBL6091196

SCHEMBL6091196

CC(C)(C)c1cc(CO)cc(C(C)(C)C)c1OCOCC[Si](C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 1/20 0.32
DHFR P00374 1/20 0.31
MEN1 O00255 1/20 0.30
GMNN O75496 1/20 0.30
GABBR2 O75899 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C9 P11712 1/20 0.30
ALOX15 P16050 1/20 0.30
TSHR P16473 1/20 0.30
NFKB1 P19838 1/20 0.30
MAPK1 P28482 1/20 0.30
CYP2C19 P33261 1/20 0.30
BLM P54132 1/20 0.30
PMP22 Q01453 1/20 0.30
KMT2A Q03164 1/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092944 0.86 CYP3A4 (0.32) CYP3A4CYP2D6DHFRALOX5APFEN1
SCHEMBL6094193 0.79 CYP3A4 (0.31) CYP3A4CYP2D6
SCHEMBL7751119 0.78
SCHEMBL23580911 0.76 HSD17B10 (0.40) ALDH1A1ALOX15TSHRMAPK1ALOX5AP
SCHEMBL7753389 0.76
SCHEMBL8736639 0.76
SCHEMBL9301504 0.74 ALDH1A1 (0.39) CYP3A4CYP2D6DHFRMEN1GMNN
SCHEMBL81656 0.73 S1PR1 (0.44) ALOX5APFEN1
SCHEMBL5281505 0.72 HRH3 (0.40) CYP3A4MEN1ALDH1A1LMNATP53
SCHEMBL23580858 0.71 NPC1 (0.41) ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ATHEROGENICS, INC. 2006-03-23 US disclosed
WO-2006004903-A2 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF ATHEROGENICS, INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ABCB11, CEL, CYP46A1 CYP3A4 51/4885CYP2D6 14/4885DHFR 2713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.